Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 5Thyroid Cancer, Papillary 2Carcinoma, Non-Small-Cell Lung 2Thyroid Diseases 1Thyroid Carcinoma, Anaplastic 1Sexual Dysfunction, Physiological 1Neoplasms 1Gastrointestinal Neoplasms 1Eunuchism 1Erectile Dysfunction 1Carcinoma, Medullary 1Cachexia-Anorexia Syndrome 1Breast Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1Adenocarcinoma, Follicular 1

Interventions

trametinib 8dabrafenib 7pembrolizumab 5Paclitaxel 5lenvatinib 4Radiotherapy, Intensity-Modulated 3Doxorubicin 3fosbretabulin 2cobimetinib 2cemiplimab 2atezolizumab 2Vemurafenib 2Sorafenib 2Nivolumab 2Bevacizumab 2zimberelimab 1tremelimumab 1selpercatinib 1sapanisertib 1sacituzumab govitecan 1pegfilgrastim 1fludarabine 1efatutazone 1durvalumab 1ceritinib 1cabozantinib 1aldesleukin 1abemaciclib 1Thyroidectomy 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid Carcinoma, Anaplastic × selpercatinib × Clear all
NCT04759911 2026-05-20

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
30 enrolled
EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡